No abstract

FCGR2A, ORAI1 and CD40 are all involved in the immune and inflammatory responses in the human body, whereas its association with lung cancer is still unclear. This study aimed to investigate the effects of polymorphisms in these genes on the susceptibility to lung cancer. Six candidate single nucleotide polymorphisms (SNPs) were genotyped using a MassARRAY platform in a discovery cohort, including 400 lung cancer patients and 400 healthy controls, and validated in a replication cohort, including 529 lung cancer cases and 532 controls. Comparing the allele frequency distributions, we found that the rs1801274-G, rs511278-T and rs1883832-T were risk alleles for lung cancer (P < 0.05), whereas the minor allele of rs12320939-T was a protective allele for the disease (P = 0.037). Comparing the genotype frequency distributions, we found that rs1801274-GG, rs511278-CT and of rs1883832-TT were risk genotype for lung cancer (P < 0.05). Genetic model analysis showed that the rs1801274 A>G was correlated with an elevated risk of lung cancer in recessive and log-additive models (P < 0.05); rs511278 C>T exhibited an increased risk of disease in dominant and log-additive models (P < 0.05); rs1883832 C>T had a strong relationship with risk of disease in all three models (P < 0.001), whereas rs12320939 G>T was correlated to a reduced risk of disease in recessive and log-additive models (P < 0.05). Finally, the association between the above SNPs and lung cancer risk was validated in a replication cohort (P < 0.05). These results shed new light on the association between immune-related genes and risk of lung cancer, and might be useful for the identification of high-risk individuals.

Objective: To analyse the expression of serum periostin in patients with non-small cell lung cancer (NSCLC) and its clinical significance. Study Design: Descriptive study.

This paper studies the mechanism of Lycium barbarum polysaccharide (LBP) in adverse reactions after immunotherapy. Five groups including model group, low-dose LBP group, middle-dose LBP group, high-dose LBP group, and interleukin-2 (IL-2) inhibitor group were set up. Adverse reactions after immunotherapy were observed through staining, blood collection and related experiments. IL-2 content was detected by ELISA, RT-qPCR and Western blot. The correlation coefficient between adverse reactions and prognosis was analyzed by Pearson software. LBP improved the diarrhea after immunotherapy and inhibition of IL-2 made the diarrhea more serious. Neutrophils around the hair follicles in the high-dose LBP group were less while they were more in model group where the hair follicles were blocked. The follicles in model group were more swelled while the follicles of high-dose LBP group had fewer swollen follicles. The degree of liver damage was inversely proportional to the concentration of LBP and the inhibition of IL-2 increased liver damage. The increased LBP promoted the improvement of immune function. LBP had a positive correlation with IL-2 level. The expression of IL-2 and E-cadherin increased with increased LBP concentration. Further analysis showed a negative correlation between diarrhea, ALT activity and AST activity and E-cadherin expression. Positive correlation between CD4+/CD8+ level and E-cadherin was observed. Conclusively, LBP could reduce adverse reactions after immunotherapy and promote IL-2 expression. IL-2 is related to immune function and its decrease causes more serious adverse reactions after immunotherapy. Thus, LBP can control IL-2 expression to reduce the adverse reactions after immunotherapy.